Xpovio (Selinexor)

Save up to 65% on Xpovio - called Nexpovia in Europe.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine.

European Manufacturer(s): Stemline Therapeutics B.V. Basisweg 10, 1043 AP Amsterdam Netherlands Berlin-Chemie AG Glienicker Weg 125 12489 Berlin Germany

Information about Xpovio (Selinexor)

Xpovio (selinexor) is an oral medication used to treat certain types of cancer. It is classified as a selective inhibitor of nuclear export (SINE). Xpovio works by inhibiting a protein called exportin 1 (XPO1), which is responsible for transporting tumor suppressor proteins out of the nucleus of cancer cells. By blocking XPO1, Xpovio helps these tumor suppressors accumulate in the nucleus, allowing them to work more effectively and ultimately leading to the death of cancer cells.

Product Highlights

• Xpovio is approved for the treatment of relapsed or refractory multiple myeloma in combination with other medications, such as dexamethasone.
• Xpovio is also used for the treatment of relapsed or refractory DLBCL in patients who have not responded to previous therapies.

Key Ingredient

• Selinexor

Key Benefits

• Xpovio targets the XPO1 protein, which is responsible for transporting key tumor suppressor proteins out of the nucleus of cancer cells. By blocking this action, Xpovio helps cancer cells die.
• Xpovio provides a treatment option for patients with cancers that have not responded to previous therapies or have relapsed after initial treatment, particularly in multiple myeloma and DLBCL.
• Xpovio is taken as an oral tablet, which offers the convenience of at-home treatment compared to other intravenous therapies.
• Xpovio can be used in combination with other drugs (like dexamethasone for multiple myeloma), enhancing the effectiveness of cancer treatment.

Direction of Use

• The recommended dose of Xpovio varies based on the specific type of cancer and whether it is being used in combination with other treatments. For multiple myeloma, the typical dose is 80 mg taken orally twice a week, in combination with dexamethasone. The dose for DLBCL is usually 60 mg once a week. The exact dosage will be determined by your doctor based on your condition. 
• Xpovio should be taken orally with water, either with or without food. It should not be crushed or chewed; it should be swallowed whole.
• If a dose is missed, take it as soon as you remember, unless it's close to the time for your next scheduled dose. Do not take two doses at once to make up for the missed dose.
• Blood tests and other evaluations will be necessary to monitor your response to treatment, potential side effects, and overall health status.

Safety Concerns

• Common side effects of Xpovio include nausea, vomiting, fatigue, loss of appetite, diarrhea, and low blood cell counts (such as anemia, neutropenia, and thrombocytopenia). These side effects should be reported to your healthcare provider for management.
• Due to its effects on blood cells, Xpovio can lower immune function and increase the risk of infections. Patients should be monitored for signs of infection, such as fever, chills, and sore throat.
• Liver enzyme levels may increase during treatment, so regular monitoring of liver function is necessary.
• Xpovio can cause low levels of red blood cells (anemia), white blood cells (neutropenia), and platelets (thrombocytopenia), leading to fatigue, increased risk of infections, and bleeding problems.
• Nausea, vomiting, and diarrhea are common side effects that may require supportive care to manage.
• Xpovio may cause imbalances in electrolytes, such as potassium and magnesium, so regular monitoring is needed.

Avoid Xpovio (Selinexor) If

• If you have a known allergy to selinexor or any of the other ingredients in Xpovio, you should not take this medication.
• Xpovio should be avoided in patients with severe liver impairment, as it can worsen liver function and increase the risk of liver-related side effects.
• If you have a history of severe low blood cell counts (bone marrow suppression), your healthcare provider will need to closely evaluate whether Xpovio is appropriate for you.
• Xpovio may cause harm to an unborn baby. Women who are pregnant or planning to become pregnant should not take Xpovio, and effective contraception should be used during treatment.
• It is not known whether Xpovio passes into breast milk. Women who are breastfeeding should discuss the risks with their doctor and avoid breastfeeding while on this medication.